Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%. Elsewhere, the ...

BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional ...

Shares of Gilead Sciences Inc. GILD inched 0.44% higher to $91.09 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a ...

Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? Let ...

Note to readers: The Daily Edition will not be published Dec. 23 through Jan. 1. Look for it again in your inbox on Jan. 2.

The cyberattack happened earlier this year, the company disclosed. Other industry news comes from CVS, Gilead, Ionis, and more.

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

So-called low- or minimum-volatility ETFs can still be risky. Many of them own top techs stocks and have lagged behind the ...